- Home
- TNXP vs NMG Comparison
TNXP vs NMG Comparison
Compare TNXP & NMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- NMG
- Stock Information
- Founded
- TNXP 2007
- NMG 2011
- Country
- TNXP United States
- NMG Canada
- Employees
- TNXP N/A
- NMG N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- NMG Other Metals and Minerals
- Sector
- TNXP Health Care
- NMG Basic Materials
- Exchange
- TNXP Nasdaq
- NMG Nasdaq
- Market Cap
- TNXP 207.5M
- NMG 245.1M
- IPO Year
- TNXP N/A
- NMG 2017
- Fundamental
- Price
- TNXP $33.33
- NMG $1.71
- Analyst Decision
- TNXP Strong Buy
- NMG Strong Buy
- Analyst Count
- TNXP 2
- NMG 2
- Target Price
- TNXP $585.00
- NMG $2.58
- AVG Volume (30 Days)
- TNXP 1.1M
- NMG 44.4K
- Earning Date
- TNXP 08-15-2025
- NMG 08-13-2025
- Dividend Yield
- TNXP N/A
- NMG N/A
- EPS Growth
- TNXP N/A
- NMG N/A
- EPS
- TNXP N/A
- NMG N/A
- Revenue
- TNXP $10,041,000.00
- NMG N/A
- Revenue This Year
- TNXP $11.66
- NMG N/A
- Revenue Next Year
- TNXP $793.18
- NMG N/A
- P/E Ratio
- TNXP N/A
- NMG N/A
- Revenue Growth
- TNXP N/A
- NMG N/A
- 52 Week Low
- TNXP $6.76
- NMG $1.22
- 52 Week High
- TNXP $137.25
- NMG $2.58
- Technical
- Relative Strength Index (RSI)
- TNXP 52.50
- NMG 47.19
- Support Level
- TNXP $33.41
- NMG $1.70
- Resistance Level
- TNXP $37.42
- NMG $1.89
- Average True Range (ATR)
- TNXP 3.48
- NMG 0.07
- MACD
- TNXP -1.12
- NMG -0.01
- Stochastic Oscillator
- TNXP 33.66
- NMG 30.43
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.